Enabling clinical transition through enhanced drug loading and stability in nanoparticle formulations
Two IND-stage drug candidates, act simultaneously as agonists of toll-like receptors TLR4 and TLR7. The compounds are intended to be delivered in liposomes or lipidic nanoparticles, but the drug load was insufficient. The goal was to perform the computational search for optimal lipid composition for both formulations, which maximizes the drug load in liposomes and ensures structural integrity and optimal size of nanoparticles for different molar ratios of the drugs.
Results for liposome formulation:
Computational screening of 24 lipid compositions allowed us to select 3 compositions, which maximize the free energy of drug incorporation into the lipid membrane and thus should have the best drug load. Experimental validation confirmed these findings with the increase of drug load up to 20 times in comparison to the initial lipid composition.
Results for nanoparticle formulation:
It was shown that the stable nanoparticles of desirable sizes are formed by compound #1 or by the mixture of both compounds with a molar ratio up to 1:1. Higher ratios lead to the formation of undesirable amorphous aggregates. These results are currently used in the experimental optimization of nanoparticle formulation.